Previous 10 | Next 10 |
PARSIPPANY, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company (“BD”), today reported financi...
PARSIPPANY, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (NASDAQ: EMBC), one of the largest pure-play diabetes care companies, announced today that its Board of Directors declared a quarterly cash dividend of $0.15 for each issued and outstanding share of ...
Yacktman's 13F equity portfolio value decreased from $11.21B to $9.64B this quarter. Yacktman Asset Management added Warner Bros. Discovery and Embecta Corp. while decreasing Sysco Corporation and Coca-Cola Company. Yacktman’s largest five stakes are at ~31% of the portfoli...
PARSIPPANY, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (NASDAQ: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today announced that it will report ...
Embecta has a history of profitability, a strong base of revenues, and good free cash flow generation. Diabetes is a large market whose patients are obliged to use insulin for the rest of their lives. This provides a lot of support for the company’s economics. Embectaȁ...
Embecta Corp. (EMBC) Q2 2022 Results Earnings Conference Call May 13, 2022, 08:00 AM ET Company Participants Devdatt Kurdikar - President and Chief Executive Officer Jake Elguicze - Senior Vice President and Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Securities...
The following slide deck was published by Embecta Corp. in conjunction with their 2022 Q2 earnings call. For further details see: Embecta Corp. 2022 Q2 - Results - Earnings Call Presentation
Gainers: Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. SomaLogic (SLGC) +19%. Veru (VERU) +18%. Celularity (CELU) +17%. Losers: Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%. Embecta (EMBC) -7%. Wave Life Sciences (WVE) -5%. ...
Embecta press release (NASDAQ:EMBC): Q2 GAAP EPS of $1.38. Revenue of $274.5M (-3.4% Y/Y). For further details see: Embecta GAAP EPS of $1.38, revenue of $274.5M
PARSIPPANY, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today reported financial results for ...
News, Short Squeeze, Breakout and More Instantly...
PARSIPPANY, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal third quarter 2024 financial results, provide an operational upd...
PARSIPPANY, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, presented two abstracts at the American Diabetes Association’s 84 th Scientific Sessions that point to ...
2024-06-21 06:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...